Prostate cancer
-
A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC 【Product for Licensing】
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Warmest congratulations to Merck and Orion, and to prostate cancer patients!
